Ken Masubuchi
Ota, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR-mutant NSCLC After TKI Resistance.
Journal: Anticancer research
Published: February 28, 2026
Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression.
Journal: ESMO real world data and digital oncology
Published: February 06, 2026
Nivolumab plus ipilimumab-based treatment in Japanese patients with metastatic non-small cell lung cancer and tumor PD-L1 < 1%: a pooled analysis.
Journal: International journal of clinical oncology
Published: February 04, 2026
Prognostic significance of post-bronchoscopy sputum cytology in lung cancer diagnosed by bronchoscopy: a retrospective cohort study of 625 patients.
Journal: Journal of thoracic disease
Published: January 24, 2026
Concurrent Chemoradiotherapy with Daily Low-Dose Carboplatin in Older Patients with Unresectable Locally Advanced Non-Small-Cell Lung Cancer: Clinical Outcomes and Prognostic Significance of Systemic Inflammation Markers.
Journal: Current oncology (Toronto, Ont.)
Published: January 07, 2026
Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study.
Journal: International journal of clinical oncology
Published: May 05, 2025
Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients With Advanced Nonsmall Cell Lung Cancer Harboring EGFR Mutations.
Journal: Clinical lung cancer
Published: April 30, 2025
Impact of EGFR Mutation Subtypes on Response to Chemoimmunotherapy and Chemotherapy in Non-Small-Cell Lung Cancer After EGFR-TKI Failure.
Journal: Targeted oncology
Published: April 08, 2025
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 09, 2025
Clinical significance of post‑progression survival after chemoradiotherapy on overall survival in limited‑disease small cell lung cancer.
Journal: Molecular and clinical oncology
Published: November 25, 2024
Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 21, 2024
A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040).
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: October 13, 2024
Last Updated: 09/26/2026